RMD Stock: Price, Earnings History and SEC Filings
ResMed Inc. (RMD) last traded at $229.94, down 9.05% on the latest session and up 4.0% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $2.91 against an analyst estimate of $2.67, a beat of 9.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
RMD earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $2.91 | $2.67 | +8.99% |
| Jun 2026 | Aug 6, 2026 | $2.95 | $2.90 | +1.72% |
| Mar 2026 | Apr 30, 2026 | $2.86 | $2.79 | +2.51% |
| Dec 2025 | Jan 29, 2026 | $2.81 | $2.69 | +4.46% |
RMD beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How RMD reacts to earnings
Across its last 8 earnings releases, RMD moved 5.0% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-29 | After close | -9.05% |
| 2026-08-06 | After close | -5.06% |
| 2026-07-07 | After close | -6.33% |
| 2026-04-30 | After close | -4.11% |
| 2026-01-29 | After close | +0.27% |
| 2025-10-30 | After close | -2.13% |
| 2025-07-31 | After close | +2.67% |
| 2025-04-23 | After close | +10.10% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
RMD financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2026 | $5.7B | $1.5B | $1.6B | 26.9% | $10.43 |
| 2025 | $5.1B | $1.4B | $1.7B | 27.2% | $9.51 |
| 2024 | $4.7B | $1.0B | $1.3B | 21.8% | $6.92 |
| 2023 | $4.2B | $898M | $574M | 21.3% | $6.09 |
| 2022 | $3.6B | $779M | $216M | 21.8% | $5.30 |
| 2021 | $3.2B | $475M | $634M | 14.8% | $3.24 |
| 2020 | $3.0B | $622M | $707M | 21.0% | $4.27 |
| 2019 | $2.6B | $405M | $390M | 15.5% | $2.80 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for RMD
- 10-Q · Oct 30, 2026
- 8-K · Oct 29, 2026Results of operations, Other events, Financial statements and exhibits
- DEF 14A · Oct 1, 2026
- 8-K · Sep 1, 2026Other events
- 8-K · Aug 17, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 10-K · Aug 13, 2026
- 8-K · Aug 6, 2026Results of operations, Other events, Financial statements and exhibits
- 8-K · Jul 7, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · May 1, 2026
- 8-K · Apr 30, 2026Officer or director change, Financial statements and exhibits
Insider filing activity
RMD insiders filed 10 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
RMD news
- RMD Q3 deep dive: product innovation and supply chain execution drive results amid evolving landscapeOct 31, 2026 · finance.yahoo.com
- ResMed (RMD) Looks Fully Valued After Another Earnings BeatOct 30, 2026 · finance.yahoo.com
- ResMed (RMD) Q1 2027 Earnings Call TranscriptOct 30, 2026 · fool.com
- ResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to SayOct 30, 2026 · finance.yahoo.com
- ResMed Inc. Q1 2027 Earnings Call SummaryOct 30, 2026 · app.moby.co
- What ResMed (RMD) Said on Its Q1 Earnings CallOct 30, 2026 · marketbeat.com
- RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin ClimbsOct 30, 2026 · finance.yahoo.com
- ResMed (NYSE:RMD) posts better-than-expected sales in Q3 CY2026Oct 29, 2026 · finance.yahoo.com
About ResMed Inc.
ResMed Inc. (RMD) is a US-listed public company on NYSE. The SEC classifies its business as Surgical & Medical Instruments & Apparatus. It is incorporated in DE. Its fiscal year ends in June.